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Abstract Several neurotransmitter and neuromodulatory
systems can control physiological glutamatergic activity.
For example, opioid receptor ligands were shown to par-
tially inhibit N-methyl-D-aspartic acid (NMDA) receptor-
dependent glutamatergic excitotoxicity. Also, the endoge-
nous tridecapeptide neurotensin (NT) was found to mod-
ulate excessive glutamate release and glutamate receptor
activity in neurons. Alternatively to the one target–one
drug approach, it has been well documented that hybrid
compounds encompassing two pharmacophores in one
molecular scaffold can represent more potent drugs.
Moreover, such structures with dual activity can potentially
enable a reduction of undesirable side effects and/or
improved bioavailability. Herein, we describe the neuro-
protective potential of an opioid-NT hybrid peptide
(PK20), which was recently designed and synthesized
within our group. The protective properties of PK20,
assessed in an in vitro model of excitotoxic injury in
organotypic hippocampal slice cultures subjected to
NMDA, were compared to the effects caused by NT. Our
results indicate that PK20 is a potent anti-neurodegenera-
tive agent. Moreover, co-administered with NMDA, PK20
(25–100 ng/ml) dose-dependently reduced hippocampal
cell death, determined by a decrease in the propidium
iodide signal. We also report for the first time the signifi-
cant NT-induced neuroprotective effect, as its application
(50–100 ng/ml) to hippocampal slice cultures protected
CA1 damage against neurotoxicity caused by NMDA.
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Glutamate, being the main excitatory neurotransmitter in
the brain, is responsible for neurodegeneration and neu-
ronal damage (Arundine and Tymianski 2004; Hynd et al.
2004; Olney et al. 1972). In fact, glutamate’s prolonged
and excessive release causes over-stimulation of its
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receptors, especially the N-methyl-D-aspartic acid (NMDA)
receptors, which consequently leads to excitotoxicity
(Mark et al. 2001). This pathological process, by which
neurons are damaged, is well-established and is well-ob-
served in, for example hippocampal pyramidal cells (CA1
region), which are known to be one of the most sensitive to
excitotoxicity. At the present time, organotypic hip-
pocampal slice culture analysis is one of the powerful
experimental approaches to examine mechanisms of neu-
ronal injury, in which the basic architecture and composi-
tion of the hippocampus is relatively preserved (Murphy
et al. 2008; Noraberg et al. 2005; Ring et al. 2010). Hip-
pocampal slice cultures exposed to NMDA or oxygen and
glucose deprivation (OGD) are being used for screening the
neuroprotective effects of new potent drugs.
By use of the hippocampal slice/NMDA model, previous
studies have shown that opioid ligands, including morphine
and the peptide biphalin, express neuroprotective properties
(Liu et al. 2008; Kawalec et al. 2011). Interestingly, both
morphine and biphalin express a ceiling protective effect
that was proposed to be directly related to the proportion of
cells containing particular neuropeptide receptor types on
their membranes. While biphalin—with a good affinity for
mu-, delta-, and kappa opioid receptors—expressed pro-
tection in as much as 65 % of the cells, mu receptor
selective ligands expressed a ceiling protective effect up to
50 % (Kawalec et al. 2011). Therefore, we hypothesized
that the activation of other neuropeptide receptors may
result in independent protection and may result in additive
or synergic effects when applied together with opioids.
This paper reports on the neuroprotective properties of
neurotensin (NT) and a peptide chimera that consists of
covalently linked NT and opioid pharmacophores. The
combination of these two elements were chosen since (i) the
brain’s opioidergic system plays an important role not only
in antinociceptive mechanisms but also in the pathophysi-
ology of neurodegenerative disorders (e.g., transient
ischemia-induced delayed neuronal cell death) (Narita et al.
2006; Vaccarino et al. 1999); (ii) kappa and/or delta opioid
receptor agonists exhibit neuroprotection by decreasing
presynaptic release of glutamate in vitro (Bradfrod et al.
1986; Chen et al. 2004; Pinnock 1992; Zhang et al. 2000) or
attenuate glutamate-dependent oxidative damage (Yang
et al. 2009); (iii) neurochemical and biochemical data
indicate that NT plays a crucial role in the regulation of
glutamatergic transmission (Antonelli et al. 2004). How-
ever, little is known about NT’s role on neurons survival.
Moreover, the physiological distribution of naturally
existing opioid and NT in the hippocampus area has been
reported (Köhler et al.1987; Li and Lei 2006).
Altogether, these data prompted us to synthesize a novel
drug type against the NMDA receptor-dependent excito-
toxicity. Such a new drug, called chimera, hybrid, or
multi-/bi-functional drug, is believed to have many
advantages including a high activity and stability to
enzymatic degradation. Additionally, its chemical structure
allows the modulation of pharmacokinetic properties and
consequently, the creation of ‘‘site specificity of action’’
(Kleczkowska et al. 2013). A compound that contains an
opioid and NT pharmacophores in one chemical structure
is thought to entail a novel entity potentially characterized
by much more stronger activity, compared to the properties
of each element alone. Indeed, as presented here, PK20 is a
novel hybrid peptide containing a modified endomorphin-2
(as an opioid pharmacophore, located on the N-terminus)
and a modified fragment of NT(8–13), which constituted
the C-terminal part of the presented chimera (Kleczkowska
et al. 2010). The insertion of several unnatural amino acids
(e.g., dimethyltyrosine, tertleucine) in the peptide chain
resulted in an improved enzymatic stability, which addi-
tionally possesses high antinociceptive potency and the
ability to cross the blood–brain barrier. Apart from PK20,
in the present study, we assumed that the opioid part can
effectively modulate the behavior of the NT analog and can
thus change its neuroprotective profile, since neurotensin
and its analogs are found to favor degenerative effects
induced by NMDA. This, in turn, may result from the
putative ability of NT and opioid receptors to form a
functionally interacting heteromeric complex.
Therefore, the aim of this study was to determine whether
a chemical hybridization of both naturally existing peptides
could influence the final profile of the compound in the
context of its neuroprotective/neurodegenerative properties.
Additionally, we would like to present neurotensin as a good
protector against NMDA-induced excitotoxicity.
Materials and Methods
Animals
Animals were provided from the Animal House of Mos-
sakowski Medical Research Centre Polish Academy of
Sciences (Warsaw, Poland). The experiments were per-
formed on male Wistar rats at postnatal days 6–7. Before
the study, all animals were housed together with their
mother rat in standard plastic cages lined with wood
shavings. A 12/12 h light–dark cycle was kept with lights
on at 0700 h. The temperature was maintained at 22 C
and the relative humidity was in the range of 55–60 %.
Food and water were freely available to the adult animals.
Reagents
Hank’s balanced salt solution (HBSS), horse serum
(HS), neurobasal, HEPES buffer, as well as antibiotic/
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antimycotic solution (AAS), and B-27 supplement were
purchased from Gibco (Poland). NMDA and propidium
iodide (PI) were purchased from Sigma-Aldrich (Poland).
PK20 was synthesized previously by Kleczkowska,
using Fmoc-strategy Solid Phase Peptide-Synthesis.
Organotypic Hippocampal Slice Culture (OHC)
Hippocampal slices were prepared from Wistar rats at
postnatal days 6–7 according to the slightly adapted
method described by Stoppini et al. (1991). In brief, ice-
cooled pups were decapitated, and the brains were placed
in ice-cold HBSS (Gibco) for further hippocampi isolation.
The hippocampi were cut into 400-lm slices using McIl-
wain tissue chopper and gently separated in a Petri dish.
Best slices were transposed onto Millicell-CM (Millipore)
membranes in a 6-well plate. Membranes were placed in
medium (pH 7.2, 50 % Neurobasal, 22 % HBSS, 5 mg/ml
glucose, 0.8 % antibiotic/antimycotic solution, and 2.5 %
HEPES 1 M) supplemented with 25 % HS, according to
Gähwiler et al. (1997). Medium was replaced every
2–3 days. From the 3rd to 8th DIV, HS was gradually
reduced by two-thirds (serum-depleted medium). Cultures
were maintained in a moist atmosphere at 36 C in 5 %
CO2.
All experimental procedures were approved by The
Local Committee for Ethics in Animal Experiments (Per-
mit Number: 14/2012).
Induction of an Excitotoxic Stress and Peptide
Treatment
After 9 days in vitro, the excitotoxic injury was induced by
the addition of 1 mM NMDA for 3 h. Then the slices were
transferred to the fresh culture medium. NT (50 and
100 ng/ml), PK20 (25, 50 and 100 ng/ml) were applied
alone or together with NMDA, and were present through-
out the experiment up to 24 h.
Additionally, selective antagonists of opioid (naltrex-
one) or NT (SR48692) receptors at concentrations of 50
and 100 ng/ml, were applied together with NMDA and
with an unchangeable dose of PK20 (50 ng/ml).
Analysis of Cell Death
After 24 h, a fluorescent death marker, PI (4.5 lM), was
added to each well. Following 30-min exposure, pho-
tographs were taken using a LSM780 laser-scanning
microscope (Zeiss, Germany). To quantify the injury
induced by either NMDA or the tested drugs, PI fluores-
cence intensity in the CA1 region (marked on the 1 mM
NMDA picture of Figs. 2a and 3a) was analyzed using a
custom-made program, and the following formula:
% of dead cells = experimental fluorescent intensity
(FI)/maximal FI 9 100, where maximal FI is obtained by
applying 10 mM NMDA.
In the present experiments, NMDA concentrations
increased up to 10 mM, despite the commonly used con-
centration to induce excitotoxicity (0.1 mM) and maxi-
mally applied one (1 mM). Our experiments showed that
commonly used NMDA concentrations in the presence of
serum (even depleted) did not induce damage.
Statistical Analysis
Data are expressed as the mean ± S.D. of at least six
independent experiments (at least four slices in each
combination, each experiment). The statistical significance
was determined by one-way ANOVA followed by Bon-
ferroni test for simultaneous analysis of multiple test
groups. The criterion for statistical relevance was estab-
lished at P\ 0.05, P\ 0.001, or P\ 0.0001. Statistical
analysis was performed with the GraphPad Prism software
version 5.0 (GraphPad Software Inc., San Diego, CA,
USA).
Results
The number of dead cells labeled with PI was counted in
order to assess the effects of NT and PK20 (structures
shown in Fig. 1) on NMDA-induced cell death.
In our model, NT (50–100 ng/ml) alone did not affect
the CA1 region at any concentration (Fig. 2). The per-
centage of PI-positive cells was 2.5 % ± 1.62 for 50 ng/ml
NT and 1.15 % ± 0.63 for 100 ng/ml NT, and no signifi-
cant difference compared to the control was observed,
where cell death always occurs spontaneously on a small
scale (i.e., 1.28 % ± 0.99).
Challenge of slices with 1 mM NMDA for 3 h caused
cell damage in the CA1 region, which in our model cor-
responded to 33.6 % ± 13. However, when NT was
applied together with NMDA, the percentage of PI-positive
cells decreased to 9.57 % ± 4.07 at an applied concen-
tration of 50 ng/ml NT and 4.67 % ± 2.41 of 100 ng/ml
NT. These values were significantly lower than the one for
NMDA alone (Fig. 2).
To examine the effects of PK20 on neuronal survival,
we used three different concentrations (25, 50, and 100 ng/
ml) of the compound. Our data showed that hippocampal
slices cultured for 24 h with this novel hybrid peptide were
almost undamaged at the lowest dose of 25 ng/ml, at which
almost no cell death was detected (1.47 % ± 1.2) (Fig. 3).
However, at higher concentrations PK20 slightly increased
cell damage in the CA1 region, and the percentage of PI-
354 Neurotox Res (2015) 28:352–360
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positive cells for 50 and 100 ng/ml of PK20 was
5.18 % ± 2.84 and 6.82 % ± 6.08, respectively. Impor-
tantly, only the highest PK20 concentration resulted in a
value statistically different (P\ 0.001) from untreated
control slices.
Co-administration of PK20 with NMDA significantly
decreased the percentage of PI-positive cells in the CA1
region compared to NMDA alone; 25 ng/ml PK20 reduced
cell damage to 13.01 % ± 8.68, representing almost 50 %
reduction in PI-positive cells. Higher concentrations of
PK20, 50 ng/ml and 100 ng/ml, reduced NMDA-induced
cell damage to 6.11 % ± 4.09 and 5.92 % ± 3.79,
respectively, so that the percentage of PI-positive cells was
almost comparable to untreated control. In fact, a statistical
difference (P\ 0.001) between PK20 100 ? NMDA and
untreated control slices was reported.
Additionally, the inhibition of opioid receptors by nal-
trexone or NTS1 receptors by SR 48692 in the presence of
NMDA and PK20 (50 ng/ml) did not annihilate the neu-
roprotective effect of PK20 (Fig. 4).
Discussion
A growing number of studies on the development and
determination of the neuroprotective potency of various drugs
have been conducted over the past few years (Yang et al.
2011a, b). In the field of neurodegenerative disease treatment,
there have also been a few articles describing the use of
compounds containing at least two chemically connected
drugs, known as hybrids, chimeras, designed multifunctional
drugs or bi/multifunctional drugs. Chiba et al. (2007) recently
presented Colivelin as a novel neuroprotective peptide that
contains an activity-dependent neurotrophic factor (ADNF)
pharmacophore and the N-terminus of a potent Humanin
derivative, AGA-(C8R)HNG17. In addition, Kawalec et al.
(2011) showed that a dimeric enkephalin, named biphalin,
protects from NMDA-mediated excitotoxicity in organotypic
hippocampal slice cultures derived from rats. However, to
date, there are no data describing any of the peptides that
contain both opioid and NT pharmacophores as compounds
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using NMDA-treated organotypic hippocampal slice cul-
tures, we are the first to present the neuroprotective activity of
PK20, an opioid-neurotensin hybrid.
Our data show that PK20 and the endogenous peptide
NT do not affect the CA1 region of the rat hippocampus
in organotypic slice cultures. Only the highest tested
Fig. 2 Dose-dependent
neuroprotective effect evoked
by the administration of
neurotensin in vitro in rat
organotypic hippocampal
cultures (OHC).
a Representative black and
white inverted photos of
hippocampal slices challenged
with 1 mM NMDA in the
presence of neurotensin NT (50
and 100 ng/ml) obtained 24 h
after excitotoxic stress. Dead
cells were visualized by
propidium iodide staining.
Polygon shows the area that was
calculated on each slice.
b Quantitative analysis of cell
death of OHC, 24 h after
glutamatergic stress. The results
are expressed as the
mean ± S.D. of propidium
iodide (PI) positive cells from at
least three independent
experiments. *P\ 0.001,
**P\ 0.0001 versus control;
##P\ 0.0001 versus NMDA
356 Neurotox Res (2015) 28:352–360
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Fig. 3 Neuroprotective activity
of PK20 opioid-neurotensin
chimera in vitro in rat
organotypic hippocampal
cultures (OHC). a Inverted
fluorescent images of propidium
iodide-stained (PI) hippocampal
slices 24 h after NMDA-
induced glutamatergic stress.
Damage was detected mostly in
the CA1 area (defined by the
line). PK20 in the different
doses (25–100 ng/ml)
administered either alone or was
co-administered with NMDA
(1 mM). b Quantitative analysis
of cell death of OHC, 24 h after
glutamatergic stress (1 mM
NMDA). The results are
expressed as the mean ± S.D.
of PI-positive cells from at least
three independent experiments.
*P\ 0.05, **P\ 0.0001
versus control; ##P\ 0.0001
versus NMDA
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concentration of PK20 (100 ng/ml) showed a slightly ele-
vated percentage of PI-positive cells, as compared to the
control. However, the CA1 damage caused by the highest
dose of PK20 differed from that exerted by 1 mM NMDA.
The low toxicity related to the peptides enabled further
analysis in the presence of NMDA receptor agonists.
In another set of experiments, we found that both con-
centrations (50 and 100 ng/ml) of PK20 and NT almost
completely abolished NMDA-induced cell death, making
the percentage of PI-positive cells comparable to that of the
NMDA-untreated control. For PK20, the lowest concen-
tration of 25 ng/ml, reduced the NMDA cell damage in the
CA1 region. These results are very promising, when con-
sidering the potential pharmacological applications. Thus,
the chemical hybridization of a NT analog together with an
opioid pharmacophore eventually produces a similar effect
to that observed for NT (Figs. 2b, 3b). Apart from the fact
that the neuroprotective activity of either NT or PK20 is
almost the same, it seems that this opioid-NT hybrid pep-
tide may be more effective in vivo as it has improved
stability against enzymatic degradation, better bioavail-
ability as well as the ability to cross the blood brain barrier
(BBB) (Kleczkowska et al. 2010). While the PK20 chimera
is characterized by the necessary CNS access
(Kleczkowska et al. 2010), NT as well as the majority of its
designed analogs does not penetrate across the blood–brain
barrier (Vincent 1995).
Additionally, hybrid structures are designed to coun-
terbalance known undesirable side effects that are intrin-
sically linked to the parent drug. Opioid treatment can
potentially result in nausea (Porreca and Ossipov 2009),
constipation (Leppert 2010), characteristic tolerance
(Benyamin et al. 2008; Cochin and Kornetsky 1964), and
physical dependence (Delander and Takemori 1983). Their
use is very controversial and may not be accepted by some
patients and therapists. Moreover, another advantage of
hybrid structures is that the can be used to effectively target
multifaceted diseases and thus may act not only on one
disease but on various co-existing conditions. This is very
important because many complex pathologies remain
inadequately treated by the commonly used principle of
‘‘one molecule–one target–one disease’’ (Decker 2011; Fuji
2011).
In addition, we have found that the partial blockade of
PK20 by means of the NTS1 receptor antagonist SR48692,
or by naltrexone as an opioid receptor antagonist, did not
produce an increased neuroprotective activity (Fig. 4).
This, in turn, may suggest that both opioid and NT moieties
are similarly involved in PK20-induced neuroprotection
and a direct additive relation between both structural ele-
ments occurred. Indeed, while testing a pure opioid phar-
macophore (data not shown) we found that this element is
crucial for the neuroprotective activity exerted by the
whole chimeric compound. Importantly, the number of
dead cells of a CA1 hippocampal region was comparable to
that observed in the control experiment (NMDA/PK20-
untreated slices). However, this does not appear to fully
explain the exact neuroprotective mechanism induced by
the chimeric compound.
Although PK20, an opioid-neurotensin hybrid peptide,
was found to be a full agonist towards either mu opioid
(Emax = 149.1 ± 2.9 % and EC50 = 70.09 ± 0.08) or
NTS1 neurotensin receptors (Emax = 141.3 ± 3.8 % and
EC50 = 66.6 ± 0.24) (data not published), it is possible
that the observed neuroprotective effect is a consequence
of activation of other receptors. Likely, NTS2 or even
kappa opioid receptor are involved. This, in turn, can result
in broadening the spectrum of interactions between com-
pound and receptors other than only opioid and neurotensin
receptors. However, to report a precise mechanism of PK20
neuroprotection, further investigations need to be carried
out. Of note, neither naltrexone nor SR 48692 exerted toxic
effects on hippocampal slices (data not shown).
We also report the involvement of NT in the protection
of a hippocampal CA1 region. Interestingly, when con-
sidering the results obtained for NT, we demonstrated that
NT did not induce any significant cell death in comparison
Fig. 4 Neuroprotective effects exerted by a combination of PK20
chimera and a selective antagonist of its each structural pharma-
cophore in vitro in rat organotypic hippocampal cultures (OHC).
Quantitative analysis of cell death of OHC, 24 h after glutamatergic
stress (1 mM NMDA). Hippocampal slices were treated with a
constant concentration of PK20 opioid-neurotensin hybrid peptide
(50 ng/ml) and with variable concentrations of either (i) selective
opioid receptor antagonist (naltrexone, NTX: 50, 100 ng/ml) or ii)
NTS1 neurotensin receptor selective antagonist (SR 48692: 50,
100 ng/ml) in the presence of NMDA. The results are expressed as
the mean ± S.D. of propidium iodide (PI) positive cells from at least
three independent experiments. **P\ 0.0001 versus NMDA
358 Neurotox Res (2015) 28:352–360
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to either untreated slices (control) or NMDA-treated cul-
tures. Although our in vitro observations are very inter-
esting, it should be taken into account that endogenous NT
was shown to increase glutamate release in the striatum,
globus pallidus, frontal cortex, and substantia nigra (Fer-
raro et al. 2011) implicating the role of NT in conditions,
such as stroke or Alzheimer’s disease. The fundamental
reason for such differences is unknown.
In conclusion, the opioid-NT hybrid peptide PK20 pre-
sents neuroprotection against NMDA-mediated excitotox-
icity in rat organotypic hippocampal slice cultures. Such
neuroprotective properties validate the approach of using
chimeric drugs with designed multitarget properties.
Moreover, when the examined chimera was tested in the
presence of selective opioid or NT receptor antagonists,
PK20’s neuroprotective activity did not result from either
opioid structural elements or the NT pharmacophore.
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